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Increased Renal Clearance of 
Rocuronium Compensates for 
Chronic Loss of Bile Excretion,  
via upregulation of Oatp2
Long Wang1,*, Mai-Tao Zhou2,*, Cai-Yang Chen3, Wen Yin3,*, Da-Xiang Wen3,  
Chi-Wai Cheung4, Li-Qun Yang3 & Wei-Feng Yu1,3
Requirement for rocuronium upon surgery changes only minimally in patients with end-stage liver 
diseases. Our study consisted of both human and rat studies to explore the reason. The reduction rate of 
rocuronium infusion required to maintain neuromuscular blockade during the anhepatic phase (relative 
to paleohepatic phase) was examined in 16 children with congenital biliary atresia receiving orthotopic 
liver transplantation. Pharmacodynamics and pharmacokinetics of rocuronium were studied based 
on BDL rats. The role of increased Oatp2 and decrease Oatp1 expressions in renal compensation were 
explored. The reduction of rocuronium requirements significantly decreased in obstructively jaundiced 
children (24 ± 9 vs. 39 ± 11%). TOF50 in BDL rats was increased by functional removal of the kidneys 
but not the liver, and the percentage of rocuronium excretion through urine increased (20.3 ± 6.9 vs. 
8.6 ± 1.8%), while that decreased through bile in 28d-BDL compared with control group. However, 
this enhanced renal secretion for rocuronium was eliminated by Oatp2 knock-down, rather than Oatp1 
overexpression (28-d BDL vs. Oatp1-ShRNA or Oatp2-ShRNA, 20.3 ± 6.9 vs. 17.0 ± 6.6 or 9.3 ± 3.2%). 
Upon chronic/sub-chronic loss of bile excretion, rocuronium clearance via the kidneys is enhanced, by 
Oatp2 up-regulation.
Rocuronium is steroidal neuromuscular blocking agent with a rapid onset and intermediate duration of action1. 
Rocuronium is eliminated primarily as unchanged molecule in the bile, with only minor contribution of urinary 
elimination2–4.
However, two previous human studies reported that rocuronium infusion requirement was not significantly 
reduced in the anhepatic phase of liver transplantation5,6. Also, plasma clearance of rocuronium was not influ-
enced by end-stage liver diseases7,8. Based on these observations, extra-hepatic clearance for rocuronium is rea-
sonable to be inferred. Obviously, the kidneys are the most likely candidate for such alternative pathway6.
Organic anion transporting polypeptides (rodents: Oatps; human: OATPs) are a superfamily of transmem-
brane transporters that eliminates a wide variety of structurally unrelated amphipathic organic compounds, 
including rocuronium, bile salts and thyroid hormones9–12. Impaired bile secretion, such as upon cholestasis, 
alters the expression of Oatps in the kidneys and cholangiocytes13,14. We therefore examined the expression of 
Oatps in the liver and kidneys upon bile duct ligation (BDL) in the current study.
The current study consisted of a human study which examined the requirement of rocuronium to main-
tain neuromuscular blockade in anhepatic phase of orthotopic liver transplantation (OLT), and rat studies to 
determine the possible contribution of the kidneys to rocuronium clearance under the condition of impaired 
bile secretion. In human study, the reduction of rocuronium infusion requirement during the anhepatic phase 
(relative to paleohepatic phase) of OLT was examined in 16 children with congenital biliary atresia. The rat 
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experiments were conducted on 7 or 28 days after ligating the bile duct. Potential contribution of the renal excre-
tion vs. hepatic secretion on rocuronium clearance was examined by functionally removing the liver vs. kidneys 
(pharmacodynamics) and by concentration determination (pharmacokinetics). The underlying mechanisms 
focused on Oatp1 and Oatp2 in kidneys were explored by Oatp2 knock-down and Oatp1 overexpression via 
adeno-associated virus (AAV).
Results
Human studies. Sixteen children were included in this study. Demographic and clinical information includ-
ing age, gender, weight, total bilirubin, serum albumin, PT and ascites, whether undergoing Kasai portoenteros-
tomy, CTP score, was shown in Table 1
The onset time after rocuronium bolus injection (Fig. 1A) and no reaction period of TOF (time from T1 
disappearing to appearing, Fig. 1B) in obstructively jaundiced (OJ) children were significantly larger than that 
in control group (93 ± 13 vs. 72 ± 10 s; 58 ± 10 vs. 43 ± 6.3 min, respectively). The requirement of rocuronium to 
maintain a stable neuromuscular blockade was significantly lower in obstructively jaundiced group during the 
anhepatic phase (2.4 ± 0.57 vs. 3.3 ± 0.97 μ g• kg−1• min−1, Fig. 1D), while the reduction of rocuronium require-
ment during the anhepatic phase (relative to paleohepatic phase), which negatively correlated with the degree of 
extrahepatic compensation, significantly decreased in OJ group compared with that in control group (24 ± 9 vs. 
39 ± 11%, Fig. 1E). The reduction of rocuronium negatively correlated with serum bilirubin (r2 = 0.27, p = 0.037, 
Fig. 1G).
Rat experiments. 7d-BDL increased serum bilirubin (445 ± 163 vs. 155 ± 99μ mol·L−1, p < 0.01). The major-
ity of elevated bilirubin was the conjugated type. 7d-BDL alone potentially increased TOF50 (11 ± 8.3 vs. 4.5 ± 3.4 
and 28 ± 15 vs. 13 ± 5.8 min for 1 and 5 mg• kg−1, respectively, Fig. 2A), although there was no significant differ-
ence. Removing the liver in 7d-BDL rats did not significantly affect TOF50 (no-liver vs. systemic metabollism, 
13 ± 5.8 vs. 20 ± 9.9 min; p > 0.05; Fig. 2B). Removing the kidneys in 7d-BDL rats increased TOF50 (no-kidney 
vs. systemic metabolism, 73 ± 47 vs. 28 ± 15 min; p < 0.05; Fig. 2C).
After injection of rocuronium 5 mg·kg−1, The excretion percentage of the administered dose through the 
urine statistically increased in 28d-BDL group compared with control group in the first 4 hours after injection 
(20.3 ± 6.9 vs. 8.6 ± 1.8%, p < 0.05; Fig. 2D), while opposite result was observed in bile excretion (8.9 ± 3.0 vs. 
28.4 ± 9.3%, p < 0.05; Fig. 2D).
Previous studies have reported that the excretion of rocuronium is mediated by Oatp1, Oatp2 and Oatp3 in 
rodents15–17. Considering the evidence that the oatp3 mRNA is undetectable in kidneys18, we mainly focused on 
the Oatp1 and Oatp2 in kidneys. BDL increased Oatp2, mostly in the glomerulus on day 14 after the surgery and 
throughout the entire nephronay on day 28 (Fig. 3A and 4). The mean positivity for Otap2 in kidney was increased 
to 20.1 ± 2.2, 24.6 ± 2.7, 28.6 ± 3.1% on 7, 14 and 28 days after the surgery, respectively vs. 17.9 ± 1.9% in Sham 
group (p < 0.05, Fig. 3B). Western blot analysis also confirmed increased Oatp2 in the kidney of BDL rats (Fig. 3C). 
Meanwhile, BDL down-regulated the mean positivity of Oatp2 in the liver (18.2 ± 2.1, 17.1 ± 1.9 and 16.9 ± 1.8% 
on 7, 14 and 28 days after the BDL surgery respectively, vs. 20.0 ± 2.2% prior to BDL, p < 0.05, Figure S1). 
The mean positivity of Oatp1 in kidney decreased (28.2 ± 3.2, 26.9 ± 2.9 and 25.9 ± 2.8% on 7, 14 and 28 days 
after the BDL surgery, respectively vs. 29.8 ± 3.4% prior to BDL, p < 0.05, Figure S2).
To assess the efficiency of AAV vectors for gene transfer into renal cells, we used H9C2, 293 AAV and HER293 
cell line, in which Oatp2 was over-expressed artificially, as an in vitro model. Figure S3A demonstrated the AAV 
Children Age (M) Gender Weight (kg) Kasai Portoenterostomy CTP PT (s)
Total Bilirubin 
(μmol•L−1)
Albumin 
(g•L−1) Ascites (ml)
Decreased 
Percentage of R* (%)
1 6.0 Female 6.5 no 11 16.0 615.8 27.1 mild 27
2 10 Female 8.0 yes 9 18.0 302.2 29.1 none 25
3 7.5 Female 8.0 no 11 20.9 578.2 34.7 none 38
4 6.0 Male 8.0 no 9 17.2 360.5 32 none 24
5 6.0 Female 8.3 no 10 14.0 247.1 25.8 mild 22
6 7.0 Male 6.8 yes 7 11.2 86.6 33.9 none 36
7 6.0 Female 6.5 yes 6 12.7 168 35.1 none 59
8 7.0 Male 6.0 yes 8 16.6 522.9 32.7 mild 6.8
9 10 Female 5.7 yes 7 9.9 176.5 39.4 none 18
10 8.0 Female 6.0 no 11 18.9 334.4 24.3 mild 33
11 12 Male 7.5 yes 6 18.9 21.0 35.7 none 43
12 12 Female 10 yes 6 15.5 86.3 45 none 39
13 7.0 Male 7.0 yes 8 11.0 293.4 31.8 none 43
14 6.0 Male 7.0 yes 8 12.0 294.1 31.2 none 33
15 6.0 Male 6.9 yes 6 13.1 109.9 35.4 none 39
16 6.0 Female 7.4 no 7 16.3 679.9 40 none 15
Table 1.  Characteristics for the Children Who Underwent Orthotopic Liver Transplantation. CTP = Child-
Turcotte-Pugh. *Reduction of rocuronium infusion requirements during the anhepatic phase relative to the 
palehepatic phase.
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vectors efficiently transduced into these cells. Meanwhile, the Oatp2 expression was also significantly inhibited 
in both mRNA (Figure S3B) and protein level (Figure S3C). The vector solutions were selectively injected into 
rat kidneys using the procedure as described in Methods. The over-expressed Oatp2 was obviously reversed by 
AAV vectors in 28d-BDL rats (Figure S3D and 5A). Figure S4 and 5A illustrated that the artificially upregulation 
of Oatp1 via AAV in kidneys was also successfully established. Oatp2 knock-down rather Oatp1 artificial upreg-
ulation in kidneys of 28d-BDL rats significantly prolonged TOF50 (blank vs. Oatp1-ShRNA, or Oatp2-ShRNA, 
15 ± 7.8 vs. 18 ± 7.5, or 36 ± 22 min, Fig. 5b), which indicated us the excretion disorder of rocuronium after 
Oatp2 knock-down. The increased urinary excretion percentage of rocuronium induced by BDL was reversed 
after Oatp2 knock-down instead of Oatp1 artificial overexpression (28-d BDL vs. Sham, Oatp1-ShRNA or 
Oatp2-ShRNA, 20.3 ± 6.9 vs. 8.6 ± 1.8, 17.0 ± 6.6 or 9.3 ± 3.2%, Fig. 5C), while Oatp1overexpression and Oatp2 
knock-down in kidneys had no effects on bile excretion in BDL rats (28-d BDL vs. Sham, Oatp1-ShRNA or 
Oatp2-ShRNA, 8.9 ± 3.0 vs. 28.4 ± 9.3, 15.0 ± 5.3 or 13.9 ± 7.7%, Fig. 5C).
Discussion
The results from the human experiments in the current study demonstrated the reduction of rocuronium require-
ment during the anhepatic phase (relative to paleohepatic phase) significantly decreased in OJ group compared 
with that in control group: subjects with OJ prior to the surgery tended to require relatively higher rate of rocuro-
nium infusion in the anhepatic phase. Interestingly, the reduction of the rocuronium negatively correlated with 
serum bilirubin prior to OLT. In the experiments with BDL rats, TOF50 was increased significantly by removing 
the kidneys, but not the liver, which was consistent with another interesting finding that BDL induced alternation 
of excretion pathway for rocuronium (urine increased while bile decreased). Furthermore, the enhanced renal 
excretion was eliminated by Oatp2 knock-down rather Oatp1 upregulation in kidneys.
Figure 1. Obstructive jaundice induced extra-hepatic compensation for rocuronium clearance upon 
compromised bile secretion. (A) The onset time of rocuronium after bolus injection. (B) No reaction period of 
TOF (time from T1 disappearing to appearing. (C) Recovery index (time for T1 from 25% to 75%). (D and F) the 
infusion requirement of rocuronium to maintain a stable neuromuscular in the anhepatic (E) and neohepatic 
phase (F). (E) The reduction of rocuronium requirement in the anhepatic phase (relative to paleohepatic phase), 
which negatively correlated with the extra-hepatic compensation. (G) The negative correlation between the 
reduction of rocuronium and serum bilirubin. (H) Continuous recording of the twitch response of adductor 
pollicis to TOF stimulation. *Significantly (p < 0.05) different from control. **Significantly (p < 0.01) different 
from control.
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Figure 2. Increased renal clearance of rocuronium compensated for compromised bile secretion in BDL 
rats. (A) The TOF50 time after rocuronium bolus injection (1 or 5 mg·kg−1) in Sham and 7d-BDL groups.  
(B) Comparisons of TOF50 time after a single i.v. bolus injection of rocuronium of 1 mg·kg−1 in Sham and 7-d 
BDL rats with or without liver. (C) Comparisons of TOF50 time after a single i.v. bolus injection of rocuronium 
of 5 mg·kg−1 in Sham and 7-d BDL rats with or without kidneys. (D) Comparisons of excretion percentage 
through bile and urine between 28-d BDL rats and Sham rats. *Significantly (p < 0.05) different. **Significantly 
(p < 0.01) different.
Figure 3. Renal expression of Oatp2 was up-regulated by BDL. (A) represents expression of Oatp2 in Sham, 
7d, 14d and 28d-BDL rats detected by IHC. (B) Represents statistical analysis of positive Oatp2 in the four 
groups. (C) Western blot of Oatp2 in kidney plasma membranes from Sham (lane 1) and 7-d BDL (lane 2) 
rats. The image has been cropped and 73KD represents Oatp2. *Significantly (p < 0.05) different from Sham. 
KD = kilodaltons.
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The current finding that children with OJ tend to require higher rocuronium infusion rate for muscular block-
ade in the anhepatic phase of the OLT clearly suggested the existence of compensatory mechanisms for rocuro-
nium clearance upon compromised bile secretion. The results also suggested that the extent of the compensation 
was dependent on baseline serum bilirubin. Experiments in BDL rats clearly demonstrated that this compensa-
tion occurs in the kidneys. In contrast to significantly prolonged TOF50 by kidney removal, removing the blood 
supply to the liver in 7d-BDL rats did not significantly affect rocuronium clearance, and 28d-BDL rats tended to 
eliminate rocuronium via urinary excretion rather than bile acid pathway.
Oatps are widely expressed in a variety of organs, including the kidneys, and seem to be responsible for extra-
hepetic clearance of rocuronium. Combining the evidence that the excretion of rocuronium is mediated by 
Oatp1, Oatp2 and Oatp3 in rodents15–17 and the oatp3 mRNA is undetectable in kidney18, we mainly focused on 
the Oatp1 and Oatp2 in kidney. The altered expressions of Oatp1 and Oatp2 in kidneys and liver are consistent 
with previous studies19,20 which might contribute to reduce the accumulation of biliary components. We spec-
ulated that the surge of bilirubin or bile acids upon BDL stimulated increased expression of Oatp2 in nephron 
units. In the kidneys, Oatp2 functions as an efflux transporter upon cholestasis21. Combined with our results that 
Oatp2 knock-down rather Oatp1 overexpression in kidneys eliminated the renal compensation for rocuronium 
excretion in BDL rats, we could conclude adaptive increase of Oatp2 in kidneys could reduce plasma bile acids 
and other organic anions, such as exogenously administered rocuronium
Oatp1 in renal tubules reabsorb a number of organic compounds that reached the renal tubles22. Oatp2 in the 
liver represents a high-affinity backup system for removal of certain cholephilic substances from portal blood23. 
Lower expression of Oatp1 in the kidneys and Oatp2 in liver of BDL rats discovered in the current study are con-
sistent with increased renal excretion and decreased hepatic secretion upon hepatic damage, although the Oatp1 
has been proved to play no role in renal enhanced excretion of rocuronium in the present study.
Figure 4. Immunofluorescent for renal expression of oatp2 from Sham and BDL rats: A1 Sham rats; A2 7d-
BDL rats; A3 14d-BDL rats; A4 28d-BDL rats. DAPI appears as a blue signal. Antibodies to Oatp2 were labeled 
with fluorescein isothiocyanate (FITC), which appears as a green signal.
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Pregnane X receptor (PXR) response elements could be detected on the Oatp2 gene and the Oatp2 was 
up-regulated in PXR knockout mice24,25. Bile acids as signaling molecules could activate the nuclear hormone 
receptors PXR. So, the up-regulation of Oatp2 in kidneys may attribute to the activated PXR. BDL is also associ-
ated with inflammation. Serum levels of pro-inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 
(IL-6), and tumor Necrosis Factor alpha (TNF-α ), are elevated in BDL rats26,27. Recombinant TNF-α , IL-1, and 
IL-6, are each capable of producing down-regulation of Oatp2 mRNA expression in mice28–30. However, the spe-
cific cellular and molecular mechanisms responsible for cytokines-related regulation of Oatp2 remains to be 
determined.
In a few previous studies5,6, reduction of rocuronium requirement in the anhepatic period (relative to that 
in the paleohepatic phase) is less prominent than that in the current study. Several possible explanations could 
account for the difference. First, we did not adopt the commonly used veno-venous bypass during the anhepatic 
period, since blocking the inferior vena cava could decrease blood flow to the kidneys6. As a result, renal clearance 
of rocuronium might have been reduced. Also, the different results may be caused by different subjects adopted 
which were children with congenital biliary atresia, other than adults with end-stage liver diseases.
Neither electromyography (EMG) nor mechanomyography was used in the current study. Despite of this lim-
itation, we have been using the acceleration transducer to monitor neuromuscular function in similar study, with 
consistent results31–34. Specifically, our results correlated well with the results obtained using mechanomyography 
or EMG35. Also, TOF50 time was measured using a bioassay, representing a weakness of the study.
In conclusion, kidneys play a prominent role in the clearance of rocuronium when excretion through the bile 
is diminished, via increased expression of Oatp2 in kidneys. The results from the current study encourage the use 
of rocuronium in patients with cholestasis.
Methods
Clinical study. Patients and Anaesthesia. The protocol was approved by the Institutional Ethics Committee 
of the Renji Hospital and the Shanghai Jiao Tong University. The methods used in our article have been car-
ried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for 
Figure 5. Renal compensation for rocuronium clearance was eliminated by Oatp2 knock-down in kidneys. 
(A) The renal Oatp1 and Oatp2 expressions in 28d-BDL rats administered with blank solution, AAV-rSlco1a1 or 
rSlco1a2 ShRNA. The image has been cropped and 90KD represents Oatp1 and Oatp2. (B) TOF50 time in 28d-
BDL rats administered with blank solution, AAV-rSlco1a1 or rSlco1a2 ShRNA. (C) Comparisons of excretion 
percentage through bile acid and urine among Sham and 28-d BDL rats administered with blank solution, AAV-
rSlco1a1 or rSlco1a2 ShRNA. *Significantly (p < 0.05) different.
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experiment involving human. All subjects’ guardians gave written informed consent prior to the study. The study 
is registered with www.chictr.org.cn, number ChiCTR-OOC-16008707.
The study included 16 children with congenital biliary atresia (10 underwent Kasai portoenterostomy) sched-
uled to receive OLT under general anaesthesia during a period from July to September 2016. The subjects were 
divided into two groups according to serum bilirubin (n = 8): obstructively jaundiced group (OJ) and control 
group. Patients who had one or more of the following conditions were not included: a neuromuscular disease 
such as one of multiple sclerosis, Huntington’s disease, Creutzfeldt-Jakob disease, myasthenia gravis or polymy-
ositis ect. Chronic kidney diseases and acute renal failure. Anaesthesia was induced with ketamine (5–8 mg• kg−1, 
i.m.) and fentanyl (5 μ g• kg−1, i.v.). After the induction, rocuronium (Esmeron® , 0.6 mg• kg−1) was immediately 
given as an intravenous bolus to facilitate tracheal intubation. Anaesthesia was maintained with propofol and 
rocuronium infusion. Patients were ventilated mechanically with oxygen and air to maintain end-tidal carbon 
dioxide in the range 30 to 40 mmHg. Blood potassium was maintained at > 3.5 mmol• L−1. Blood calcium was 
maintained at > 1.0 mmol• L−1. Urine output was measured hourly. During the anhepatic phase, portal vein and 
hepatic vein were completely blocked, instead of bypassing the veno-venous bypass from the lower limbs and 
portal vein to the jugular vein.
Rocuronium Infusion. Rocuronium infusion was commenced when the twitch response in the adductor pol-
licis muscle to train-of-four (TOF) stimulation fully recovered from the initial bolus injection (0.6 mg• kg−1, 
as described above). Rocuronium was infused at an initial rate of 0.3 μ g• kg−1• min−1, and adjusted to maintain 
85–95% neuromuscular paralysis. The infusion rate must be stable for at least 20 min to be included in the analysis 
of rocuronium requirement.
Neuromuscular function monitoring. The level of neuromuscular paralysis was evaluated by measuring the 
acceleration of the adductor pollicis twitch response to asupramaximal stimulation (0.2msec duration single 
stimulus at a frequency of 0.1 Hz) to the ulnar nerve at the wrist, via the TOF-Watch®SX.
Rat experiments. All animal experiments were conducted in accordance with the Institutional Guidelines 
on the Use of Live Animals for Research, and approved by the Animal Careand Use Committee of the Second 
Military Medical University.
Adult male Sprague-Dawley (SD) rats (250–350 g) were housed under a 12 h light/12 h dark cycle at 22 °C, 
with free access to food and water until 8 hours prior to pentobarbital anaesthesia (50 mg• kg−1; i.p.) after atropine 
injection (0.25 mg• kg−1). Rats were intubated and ventilated (frequency: 90/minute; pressure: 0.015–0.02 Mpa) 
using a TKR-200 respirator. The end-tidal PCO2 was maintained at 35–45 mmHg. Twenty-one rats received BDL. 
Briefly, the common bile duct was securely ligated close to the hilus and cut between the two ligatures. A group of 
rats (n = 18) receiving Sham operation (all the procedures with the exception of BDL) was included as a healthy 
control.
On day 7 after BDL (17 BDL rats, 15 Sham operation rats), the liver was exposed and the liver artery was 
ligated. The portal vein was blocked with a vascular clamp at its distal end. The left hepatic lobe was partly excised 
to expose the portal vein along its inferior margin. A heparinized silicone catheter (diameter: 0.2 cm) was inserted 
into the portal vein. The other end of the silicone catheter was fixed in the left hepatic vein. The vascular clamp 
was then opened to allow blood flow to the left hepatic vein from the portal vein. For kidneys removal, both renal 
arteries were ligated at the pedicles.
The right hindlimb of the rat was immobilized and the sciatic nerve was isolated surgically in the popliteal 
space. A bipolar platinum electrode was attached to the peripheral portion of the nerve. The distal tendon of the 
right tibial was isolated from the surrounding tissue and connected to a force transducer (TB-611, Nihon Kohden, 
Tokyo, Japan) at a resting tension of 30 g. TOF stimulation (TOF-Watch® SX), consisting of four supramaximal 
pulses (0.2msec duration; 2 Hz), was applied to the sciatic nerve via the electrodes every 15 sec. The T1 block was 
maintained at 95-105% for at least 5 min before rocuronium administration (i.v. bolus injection of rocuronium of 
1 mg• kg−1 or 5 mg• kg−1). Neuromuscular block was monitored by measuring the time needed for TOF resump-
tion to 50% (TOF50).
In vivo rSlco1a1 or rSlco1a2 -ShRNA Transduction into the Kidneys. To achieve efficient rAAV-DJ-ZsGreen- 
rSlco1a1 or rSlco1a1 ShRNA delivery into the kidney in vivo, we used a catheter-based gene delivery system in 
rats. The flexible Solo-Cath catheter (2Fr; Solo-mon Scientific, Plymouth Meeting, Pa., USA) was inserted via 
the left iliac artery and the abdominal aorta, and the tip was placed beneath the left artery. After the aorta was 
clamped just above the left renal artery, 1 ml of AAV vector solution was injected after 1-2 ml of saline to wash 
out blood via the catheter. The left renal vein then was clamped for 10 min. Catheter and clip were removed. 
Meanwhile the BDL procedures were carried out, and rats were sacrificed on day 28.
Urine, bile acid and serum from 28d-BDL rats (n = 5) and Sham rats (n = 4) were collected 4 h after rocu-
ronium administration (i.v. bolus injection 5 mg• kg−1). Concentrations of rocuronium were measured by 
HPLC-MS (Agilent Technologies, CA, USA; Applied Biosystems Sciex, MA, USA).
Immunohistochemistry. Paraffin sections (5μ m) were deparaffinized and rehydrated. After incubation with 2% 
bovineserum albumin in Tris-buffered saline (TBS; pH 7.6) at room temperature for 30 min, sections were incu-
bated overnight at 4 °C with either an anti-oatp1 (OATP21-A, 1:200, ADI, Samford, Connecticut, America) or 
anti-oatp2 (OATP21-B, 1:200, ADI, Samford, Connecticut, America). After extensive washing, the sections were 
incubated with a polymer enhancer and a polymerized anti-rabbit or anti-mouse IgG (dilution1:200, Jingmei, 
Shanghai, China) labeled with horseradish peroxidase. The staining was visualized with a DAB kit (Maixin 
Biologic Technology, Fujian, China), and appeared as buffy granules in cytoplasm.
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Immunofluorescence. Tissue sections were prepared as described previously36. Nonspecific bindings were 
blocked with 2% bovine serum albumin (BSA) in TBS pH 7.6 at room temperature for 30 min. Then, the tis-
sue sections were incubated overnight at 4 °C with the anti-Oatps antibody. Washing was then performed at 
room temperature using TBS pH7.6. And then, the tissues were incubated with a cyber green-conjugated goat 
anti-rabbit IgG antibody (dilution1:200, Jingmei, Shanghai, China) in 2% BSA-TBS at 1:400 for 3 h. The sections 
were analyzed using a confocal fluorescencemicroscope (Nikon UFX, Tokyo, Japan).
Western blotting analysis. Crude plasma membrane (CPM) was prepared as described previously37,38, and 
separated using a 7.5% polyacrylamide gel. The proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane, and then blocked with 5% non-fat dry milkin TBST buffer containing 0.05% Tween-20 at room tem-
perature for 1 h. The membrane was then incubated overnight at 4 °C with an anti-oatp2 antibody (OATP21-B, 
1:200, ADI, Samford, Connecticut, America). After appropriate washing, the membrane was incubated for 1 h 
with an anti-rabbit IgG antibody (dilution1:200, Jingmei, Shanghai, China) for detection of Oatp2 using ECL Plus 
(Amersham Pharmacia, Piscataway,NJ) for visualization.
Statistical Analysis. Quantitative data were expressed as the mean ± SD. A Student’s t-test was used to com-
pare the measurement data of two groups. The reduction of rocuronium requirement in the anhepatic phase 
(relative to that in the paleohepatic phase) vs. serum bilirubin prior to the surgery was analyzed using a linear 
regression. Data from three or more samples were analyzed using one-way analysis of variance (ANOVA), fol-
lowed by Dunnett’s t-test (the mean positivity of Oatps in tissue samples the Sham and 7, 14, 28-day BDL groups; 
the TOF50 time among blank, Oatp1-ShRNA and Oatp2-ShRNA groups) and Tukey’s multiple comparisons test 
(the TOF50 time from Sham + systemic metabolism, Sham + no-liver or no-kidney, BDL + systemic metabo-
lism, BDL + no-liver or no-kidney; the excretion percentages of rocuronium though urine and bile). The level of 
statistical significance was set at p < 0.05. All statistical analyses were performed with PASW Statistics version 18.
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